Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the World Health Organization (WHO) accidentally posted on its website.
In response to the leaked results, since taken down by the WHO, Gilead said that the trial was stopped early and so findings remain inconclusive.
According to data, intravenous infusion of the drug did not improve patients’ condition or decrease the virus’ presence in the bloodstream, noted Reuters citing the draft documents published by the WHO.
The rate of death was similar in both the groups, with 13.9% in remdesivir arm compared to 12.8% in the placebo arm. News website STAT captured a screenshot of the publication, which showed